MGP
BBIO icon

M&G plc’s BridgeBio Pharma BBIO Stock Holding History

M&G plc’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$239K Sell
3,223
-11,818
-79% -$828K ﹤0.01% 359
2026
Q1 		$1.11M Hold
15,041
– – 0.01% 327
2025
Q4 		$1.14M Buy
+15,041
New +$987K 0.01% 321

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

M&G plc's BBIO Position: Q2 2026 in Review

M&G plc reduced its BridgeBio Pharma (BBIO) stake by 79% in Q2 2026, selling an estimated $828K and leaving 3,223 shares worth $239K. The position accounts for ﹤0.01% of the portfolio, ranked #359.

M&G plc first reported a position in BBIO in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.14M in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • M&G plc held 3,223 shares of BridgeBio Pharma worth $239K as of Q2 2026.
  • M&G plc sold 11,818 BridgeBio Pharma shares in Q2 2026, an estimated $828K.
  • BridgeBio Pharma made up ﹤0.01% of M&G plc's portfolio in Q2 2026, its #359 holding.
  • M&G plc first reported a position in BridgeBio Pharma in Q4 2025 and has held it in 3 quarters since.
  • M&G plc's BridgeBio Pharma position peaked at $1.14M in Q4 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on M&G plc's 13F filing for Q2 2026, filed 6 Aug 2026.